MGF 2mg Review

Mechano Growth Factor, abbreviated MGF, is a splice variant of insulin-like growth factor 1 (IGF-1) that has attracted sustained attention in skeletal muscle biology, cardiac repair, and neuroprotection research since its original characterization in the late 1990s. Unlike the canonical IGF-1Ea isoform, MGF carries a distinctive 49-amino-acid C-terminal E-peptide that appears to drive a separate, IGF-1 receptor-independent signaling program, at least under certain experimental conditions. ^[1]

The peptide is of particular interest to researchers studying satellite cell activation, hypertrophic signaling cascades, and the cellular response to mechanical load. A PEGylated form (PEG-MGF) was developed to address the compound's characteristically short plasma half-life and has featured in a subset of the in-vivo literature as a more pharmacologically tractable research tool. ^[2]

This review covers the Apollo Peptide Sciences MGF 2mg vial, examining the available published evidence with the same critical lens applied across all Best Peptides For You product assessments. Where evidence is thin or contested, that is noted explicitly.

Editor's Verdict

The compound earns a cautious but genuine interest rating from this editorial team. The gap between the mechanistic promise visible in cell culture and rodent data and the complete absence of human clinical trials is wider here than for some other IGF-1 axis peptides. Researchers should enter this literature with realistic expectations about translational certainty.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

The IGF-1 Gene and Its Splice Variants

The insulin-like growth factor 1 gene (IGF1, located at chromosome 12q23.2 in humans) is one of the most extensively studied loci in growth biology. ^[3] Through tissue-specific alternative splicing of exons 4, 5, and 6 in the 3' region of the pre-mRNA, the IGF1 gene generates several distinct mRNA species that share a common mature IGF-1 domain but diverge in their E-domain sequences. ^[4] The canonical systemic form, IGF-1Ea, is produced primarily by the liver under growth hormone stimulation. A second isoform, IGF-1Eb (rodent) or IGF-1Ec (human), is generated when exon 5 is included in the mRNA transcript, producing a longer E-peptide with a reading frameshift that creates an entirely different amino acid sequence in its C-terminal region. ^[1]

This IGF-1Ec isoform was renamed "Mechano Growth Factor" by Professor Geoffrey Goldspink and colleagues at University College London following their discovery that it is preferentially upregulated in skeletal muscle in response to mechanical load, exercise, and muscle damage rather than in response to systemic growth hormone. ^[1] The name reflects the trigger, not necessarily a unique receptor, though subsequent signaling work has made the receptor question considerably more complicated (see Mechanism of Action below).

The E-Peptide: What Makes MGF Different

Both IGF-1Ea and IGF-1Ec produce the same 70-amino-acid mature IGF-1 domain after proteolytic processing. The critical structural distinction is in the E-peptide region that is cleaved after translation. In the case of MGF, this E-peptide is 49 amino acids long in the full-length protein. However, the majority of research peptides sold under the "MGF" designation, and the majority of published in-vitro work, use a shorter synthetic fragment corresponding to the last 24 amino acids of the Ec E-peptide: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys. ^[5]

This 24-residue synthetic E-peptide is sometimes referred to as "MGF C-terminal peptide" or "MGF-Ct" in the literature to distinguish it from recombinant full-length MGF protein. The distinction matters when interpreting pharmacological data, because studies using the full recombinant protein versus the synthetic E-peptide fragment can produce different (and occasionally contradictory) results in assay systems, likely because the mature IGF-1 domain and the E-peptide interact with different receptors. ^[6]

PEGylation and PEG-MGF

Native MGF, whether full-length or the synthetic 24-aa fragment, has a plasma half-life in the range of minutes when administered systemically in animal models. ^[2] This rapid clearance severely limits its utility as a research tool in any in-vivo model requiring sustained tissue exposure. PEGylation, the covalent attachment of polyethylene glycol chains to the peptide, is a well-established pharmaceutical strategy to extend the circulatory half-life of peptides and proteins by increasing hydrodynamic radius and reducing renal filtration and proteolytic degradation. ^[7]

PEG-MGF, in which a methoxy-PEG chain (typically 2,000-5,000 Da) is conjugated to the N-terminus or a lysine side chain of the MGF E-peptide, extends the reported half-life to approximately 6 days in some animal model data. ^[2] This difference has practical implications for experimental design: native MGF is better suited to acute, short-window assays where the timing of peak concentration is important, while PEG-MGF is better suited to chronic administration paradigms where stable tissue exposure over days is the experimental goal. The Apollo MGF 2mg SKU refers to native (non-PEGylated) MGF unless the vendor's certificate of analysis specifies PEG conjugation; researchers should confirm this before designing experiments.

Structural Context Within the IGF Axis

To situate MGF within its broader pharmacological context, the IGF axis comprises IGF-1, IGF-2, the IGF-1 receptor (IGF-1R), the insulin receptor (IR), insulin-like growth factor binding proteins (IGFBPs 1-6), and various co-receptors and signaling adapters. ^[8] MGF, because it is processed from the same pre-mRNA as systemic IGF-1, contains the mature IGF-1 domain and is therefore capable of binding IGF-1R. However, the unprocessed or partially processed MGF protein (where the E-peptide remains attached) behaves differently from free mature IGF-1, and several lines of evidence suggest the E-peptide itself acts on a distinct receptor that does not interact with mature IGF-1 alone. ^[6] This dual-receptor hypothesis underpins much of the interest in MGF as a mechanistically distinct tool compared to recombinant IGF-1.

Mechanism of Action

Satellite Cell Activation and Proliferation

The most replicated and mechanistically detailed finding in the MGF literature concerns satellite cell activation in skeletal muscle. Satellite cells are quiescent mononuclear muscle stem cells that reside beneath the basal lamina of mature myofibers. ^[9] Following muscle damage or mechanical overload, satellite cells exit quiescence, proliferate, and either fuse with existing fibers to donate myonuclei or differentiate into new myotubes. The number of available myonuclei limits hypertrophic potential in many models, making satellite cell activation a rate-limiting step in muscle repair and adaptation.

Goldspink's group demonstrated that a synthetic peptide corresponding to the MGF E-peptide fragment increased satellite cell proliferation and reduced differentiation (fusion into myotubes) in primary cell culture, while the equivalent IGF-1Ea E-peptide had no such effect. ^[1] This suggested that the Ec E-peptide carries biological activity independent of the shared mature IGF-1 domain, driving a proliferative rather than differentiative program. The operational implication for experimental design is that MGF E-peptide and mature IGF-1 may act sequentially: MGF-driven proliferation expands the satellite cell pool, after which IGF-1-driven differentiation signals fuse those cells into fibers.

Subsequent work by Yang and Goldspink (2002) using plasmid electrotransfer of MGF into mouse tibialis anterior muscle found increased muscle fiber cross-sectional area and satellite cell numbers compared to IGF-1Ea electrotransfer, with an approximately 25% greater hypertrophic response in the MGF group over a 3-week period in young adult mice. ^[1] The small sample sizes in these foundational studies (n=6-8 per group in most cases) and the use of intramuscular gene transfer rather than systemic peptide administration limit direct extrapolation to systemic peptide research, but the directional finding has been broadly replicated.

IGF-1R-Dependent vs. E-Peptide-Specific Signaling

When the full MGF protein (mature domain + E-peptide) is applied to cells, it activates IGF-1R and the downstream PI3K-Akt-mTORC1 axis in a manner qualitatively similar to mature IGF-1. ^[8] This pathway drives protein synthesis, inhibits proteolysis via FOXO transcription factor suppression, and promotes cell survival. The phosphorylation of ribosomal S6 kinase 1 (S6K1) and 4E-binding protein 1 (4E-BP1) downstream of mTORC1 increases translational capacity at the ribosome level, which is mechanistically connected to the hypertrophic responses observed in muscle overload models. ^[10]

The E-peptide-specific signaling, by contrast, appears to operate through a receptor or receptor complex that remains incompletely characterized. Receptor binding assays have shown that the synthetic 24-aa E-peptide does not compete with IGF-1 for IGF-1R binding, yet elicits intracellular calcium transients, ERK1/2 phosphorylation, and cell cycle progression in satellite cells. ^[6] Some evidence points to a role for heparan sulfate proteoglycans (HSPGs) on the cell surface as co-receptors or concentration machinery that present the E-peptide to an as-yet unidentified receptor. ^[5] The identity of this putative MGF-specific receptor remains an active and unresolved question in the field (see Open Research Questions below).

Cardiac and Smooth Muscle Applications

The MGF E-peptide has been investigated as a potential cardioprotective agent in ischemia-reperfusion models. Xu and colleagues applied the synthetic 24-aa MGF E-peptide to isolated cardiomyocytes subjected to simulated ischemia and found dose-dependent reductions in apoptotic markers (cleaved caspase-3, cytochrome c release) and improvements in mitochondrial membrane potential. ^[11] In-vivo rat models of myocardial infarction produced by left coronary artery ligation demonstrated reduced infarct area and preserved ejection fraction at 4 weeks when the MGF E-peptide was administered by intramyocardial injection at the time of reperfusion. ^[11]

The proposed mechanism in cardiac tissue involves both IGF-1R-mediated Akt phosphorylation and a parallel pathway that reduces reactive oxygen species (ROS) generation through modulation of mitochondrial permeability transition pore (mPTP) opening. ^[12] Whether the cardioprotective effect requires the full MGF protein or can be replicated by the E-peptide alone is still debated, with different laboratories reporting conflicting results depending on the model and the peptide preparation used.

Neuroprotective Signaling

A third body of literature has examined MGF in neuronal contexts. The brain expresses IGF-1Ec mRNA, and mechanical or ischemic injury upregulates local MGF expression in neurons and astrocytes. ^[13] In-vitro assays using hippocampal neurons subjected to oxygen-glucose deprivation showed that the synthetic MGF E-peptide at nanomolar concentrations reduced LDH release (a marker of cell death), preserved dendritic morphology, and attenuated glutamate-induced excitotoxicity. ^[13]

The neuroprotective mechanism partially overlaps with the cardioprotective one: Akt/PI3K activation reduces pro-apoptotic BAX expression and increases BCL-2 expression. ^[14] An additional proposed mechanism specific to neurons involves ERK1/2-mediated CREB phosphorylation, which drives expression of neurotrophic genes including BDNF and NGF. ^[14] These findings have generated interest in MGF as a potential research tool for neurodegenerative disease models, though this literature is early-stage relative to the muscle work.

Tissue Distribution of MGF Expression

Endogenous MGF expression is not uniform across tissues. Under basal conditions, low-level IGF-1Ec mRNA is detectable in skeletal muscle, cardiac muscle, brain, and bone. ^[3] Following mechanical stimulation or injury, expression rises most dramatically in skeletal muscle (10-30 fold in exercise studies using quantitative RT-PCR in rodents) and to a lesser extent in cardiac muscle and brain. ^[1] Liver, which is the dominant site of systemic IGF-1Ea production, shows relatively low MGF expression under most conditions. This tissue specificity supports the interpretation of MGF as a local, autocrine/paracrine growth factor rather than a systemic hormone, which has implications for how exogenously administered synthetic MGF distributes and where it exerts its effects after parenteral administration in research models.

What the Research Says

Study 1, Yang and Goldspink (2002): Muscle Hypertrophy via Gene Transfer

Yang SY and Goldspink G published foundational work in the FEBS Letters journal examining differential effects of MGF versus IGF-1Ea on mouse skeletal muscle. ^[1] The experimental design involved intramuscular electrotransfer of plasmid constructs encoding either the full MGF isoform or IGF-1Ea into the tibialis anterior (TA) muscle of young adult male mice (n=6-8 per group). Measurements were taken at 3 weeks post-electrotransfer and included muscle fiber cross-sectional area (CSA) by histomorphometry, satellite cell counts by Pax7 immunostaining, and body composition.

The MGF-transfected group showed approximately 25% greater mean fiber CSA compared to the IGF-1Ea group, and approximately 32% greater fiber CSA compared to saline-injected controls. Pax7-positive satellite cell counts were elevated by roughly 45% in the MGF group relative to IGF-1Ea. The authors interpreted this as evidence that the Ec E-peptide drives preferential satellite cell expansion before differentiation signals (presumably from the IGF-1Ea isoform or endogenous IGF-1 generated after the initial hypertrophic stimulus) promote fusion.

The limitations of this study are significant in the context of research peptide use: intramuscular gene transfer produces sustained local overexpression of the full-length protein rather than the transient systemic exposure from an injected synthetic peptide. The dose delivered by plasmid electrotransfer is difficult to relate to a molar equivalent of synthetic peptide. However, as a proof-of-concept demonstration that the Ec isoform drives a different biological program than Ea, the data are widely cited and have not been refuted in subsequent literature.

Study 2, Goldspink et al. (2006): Mechanical Sensing and Splice Variant Expression

A 2006 paper from the Goldspink laboratory, published in the Journal of Internal Medicine, detailed the mechanosensitive regulation of MGF expression using a rabbit tibialis anterior stretch model and human biopsy data. ^[4] Muscle was subjected to controlled passive stretch (10% beyond resting length, 30 cycles per day for 7 days) or sham treatment, and MGF and IGF-1Ea mRNA levels were quantified by RT-PCR.

The stretched muscle showed a 4-fold upregulation of MGF mRNA within 24 hours of the first stretch session, with IGF-1Ea levels rising more gradually over the following 3-5 days. This temporal dissociation supports the sequential model: MGF responds acutely to the mechanical signal, while Ea responds to the anabolic milieu generated by the initial repair process. Human biopsy data from resistance-trained subjects showed a similar early MGF mRNA peak (2-6 hours post-exercise) followed by a later IGF-1Ea peak at 24-48 hours. ^[4] The human biopsy data in this paper are small (n=5 subjects) and should be treated as hypothesis-generating rather than definitive, but they provide a plausible framework for understanding when exogenous MGF might most effectively complement endogenous signaling in an experimental paradigm.

Study 3, Qin et al. (2014): PEG-MGF in Hindlimb Ischemia

Qin and colleagues published a study in PLoS ONE (2014) examining PEG-MGF in a rat hindlimb ischemia model, which is a commonly used preclinical proxy for peripheral vascular disease and for studying angiogenesis and muscle recovery after ischemic insult. ^[2] Animals received either saline, native MGF, or PEG-MGF by intramuscular injection into the ischemic limb immediately after surgical ischemia induction. Endpoints at 28 days included limb perfusion by laser Doppler, capillary density by CD31 immunohistochemistry, muscle fiber viability, and functional assessments.

PEG-MGF showed dramatically better outcomes than native MGF across all endpoints, which the authors attributed directly to the extended pharmacokinetic profile: native MGF was essentially cleared within 30 minutes of injection (plasma half-life estimated at approximately 5 minutes in this model), while PEG-MGF maintained measurable plasma concentrations for approximately 6 days. Capillary density in the PEG-MGF group was approximately 2.3-fold higher than in the native MGF group and 1.8-fold higher than in untreated ischemic controls. Fiber necrosis was reduced by approximately 40% in the PEG-MGF group versus saline control.

This study is among the most rigorously designed in the MGF literature from a pharmacological standpoint because it directly compared pharmacokinetic profiles and linked the PK difference to the PD outcome. The primary limitation is that the dose used (25 mcg/kg body weight intramuscular in the rat) is an animal-equivalent figure not directly translatable to other species or to in-vitro assay concentrations. See our peptide dosage calculation guide for discussion of allometric scaling principles.

Study 4, Deng et al. (2017): Cardiac Ischemia-Reperfusion and the E-Peptide

Deng et al. published data in the Journal of Translational Medicine examining the effect of the synthetic MGF 24-aa E-peptide on rat myocardial ischemia-reperfusion injury. ^[11] Ischemia was induced by 30-minute left anterior descending (LAD) artery ligation followed by 24-hour reperfusion. The MGF E-peptide was administered at doses of 1, 10, and 100 nmol/kg by intravenous injection at the time of reperfusion. Primary endpoints included infarct size (TTC staining), cardiac enzyme release (troponin I, CK-MB), and echocardiographic ejection fraction at 24 hours.

All three doses reduced infarct size relative to vehicle control (18%, 31%, and 39% reduction, respectively, for 1, 10, and 100 nmol/kg), with a roughly dose-dependent relationship. Troponin I release was reduced by approximately 35% at the highest dose. Ejection fraction was preserved at approximately 58% in the 100 nmol/kg group versus approximately 46% in the vehicle group. Mechanistic experiments in isolated cardiomyocytes confirmed Akt phosphorylation, BCL-2 upregulation, and reduced mitochondrial cytochrome c release as downstream effects.

A critical feature of this study is that the authors specifically used the E-peptide fragment alone (not the full MGF protein), and blocked IGF-1R with an antibody in a subset of experiments. The cardioprotective effect was partially but not fully attenuated by IGF-1R blockade, supporting the hypothesis that the E-peptide has some IGF-1R-independent activity in cardiac tissue. The partial persistence of effect after IGF-1R blockade does not, by itself, confirm a novel receptor, but it is consistent with the signaling data discussed in the Mechanism section above.

Study 5, Stavropoulou et al. (2009): MGF in Neuronal Protection

Stavropoulou and colleagues examined MGF expression and the protective effect of the synthetic E-peptide in a rat model of focal cerebral ischemia (middle cerebral artery occlusion, MCAO). ^[13] MGF mRNA was measurably upregulated in peri-infarct cortex and hippocampus at 6, 24, and 72 hours post-MCAO, suggesting that the endogenous system is responsive to ischemic neuronal stress. Exogenous synthetic E-peptide administered by intracerebroventricular injection (5 mcg total) reduced infarct volume by approximately 28% compared to vehicle at 24 hours and improved performance on a battery of neurological deficit scores at 72 hours.

The strength of this study lies in its dual design (endogenous expression mapping plus exogenous administration), which provides convergent lines of evidence. The primary limitations are the small group sizes (n=8 per group), the intracerebroventricular delivery route (which is not a standard systemic route and limits translation to systemic peptide research), and the single time point for the interventional arm. This study is best treated as hypothesis-generating for a potential neuroprotective role rather than as definitive efficacy data.

Open Research Questions

Several genuinely unresolved questions limit confident interpretation of the MGF literature:

The identity of the putative E-peptide-specific receptor has not been confirmed. Multiple groups have published data consistent with a novel receptor, but no receptor has been cloned, expressed, and validated with full pharmacological characterization. ^[6] Without receptor identification, it is impossible to design a proper receptor binding assay, which means purity and identity testing of synthetic MGF preparations cannot include a bioassay that is mechanistically anchored.

The relative contribution of the mature IGF-1 domain versus the E-peptide to the biological effects of full-length MGF protein preparations is not fully settled. Studies using E-peptide-only synthetic fragments, full-length recombinant MGF, and gene-transfer constructs sometimes produce different quantitative and occasionally qualitative results. ^[5] Researchers using synthetic E-peptide fragments (which is the standard commercial preparation) should be cautious about extrapolating from full-length protein studies.

The question of whether exogenously administered MGF peptide, after systemic injection, reaches skeletal muscle satellite cells in sufficient concentrations to drive the proliferative effects seen in the gene-transfer literature has not been rigorously answered in any published study. PK modeling suggests that native MGF has too short a half-life for meaningful systemic delivery, and even PEG-MGF data are limited to specific intramuscular or intravenous administration paradigms. ^[2]

Pharmacokinetics

The extremely short plasma half-life of native MGF is its defining pharmacokinetic challenge. A half-life of approximately 5 minutes after intravenous administration in the rat means that by 30 minutes, plasma concentrations have fallen to less than 1% of peak. ^[2] This does not necessarily preclude biological activity at the tissue level, because rapid receptor engagement at the site of injection or in locally perfused tissue can trigger signaling cascades that persist far longer than the peptide itself. The literature on rapid-acting peptides like growth hormone-releasing hormone (GHRH) fragments suggests that seconds-to-minutes receptor occupancy can generate hours-long downstream signaling changes via second messenger amplification. Whether this pharmacodynamic persistence applies to MGF is not clearly established in the published record.

For PEG-MGF, the extended half-life comes with trade-offs. The PEG chain, while reducing proteolysis and renal clearance, can in some cases reduce receptor binding affinity by steric hindrance, meaning that the net pharmacodynamic potency per mole of PEG-MGF may be lower than for native MGF, even though tissue exposure time is greater. The Qin et al. hindlimb ischemia study suggests the net effect favors PEG-MGF in chronic models, but this finding may not generalize to all tissue types and endpoints. ^[2]

Regarding protein binding, the mature IGF-1 domain of MGF would be expected to interact with the six IGF-binding proteins (IGFBP-1 through IGFBP-6) given the structural homology with IGF-1 itself. ^[15] IGFBP-3 is the dominant serum carrier for IGF-1 in vivo, and this interaction significantly limits free IGF-1 concentrations. Whether the E-peptide region of intact MGF alters IGFBP binding affinity relative to free mature IGF-1 is not clearly resolved. The synthetic 24-aa E-peptide fragment on its own lacks the mature IGF-1 domain and would not be expected to engage IGFBPs, which has implications for its free tissue availability after injection.

Purity and Verification

What a Robust MGF CoA Should Show

A credible certificate of analysis for a research-grade MGF peptide should contain at minimum the following elements:

HPLC purity trace: A single dominant peak corresponding to the target peptide with an area percentage of 98% or above. The trace should show the UV absorbance wavelength used (typically 214 nm for peptide bonds or 280 nm if tryptophan/tyrosine residues are prominent), the column type and mobile phase conditions, and the retention time. Retention time alone is insufficient for identity confirmation but provides a basic consistency check across batches.

Mass spectrometry confirmation: ESI-MS or MALDI-TOF data showing a molecular ion or charge-state ladder consistent with the theoretical mass of the intended sequence. For the 24-aa MGF E-peptide (theoretical monoisotopic mass approximately 2,867 Da), the mass spectrum should show a primary ion consistent with this value within 0.1-0.5 Da depending on instrument resolution. A mass that differs by more than 1 Da from the theoretical value suggests either a sequence error, a missed deprotection step, or contamination with a truncated sequence.

Endotoxin testing: Limulus Amebocyte Lysate (LAL) assay result, typically expressed in EU/mg. For peptides intended for in-vitro cell culture assays, endotoxin levels above approximately 1 EU/mg can confound cytokine, proliferation, and cell viability data, because bacterial lipopolysaccharide (LPS) activates many of the same inflammatory and survival pathways that MGF research aims to characterize. Reputable research peptide vendors typically report endotoxin below 1 EU/mg or specify a result in EU per dose equivalent.

Water content: Karl Fischer titration result or equivalent. Lyophilized peptides often contain 5-15% residual water by mass, which means a nominally 2 mg vial may contain 1.7-1.9 mg of actual peptide. Failure to account for water content introduces systematic dosing errors in concentration-response experiments.

Peptide content by AAA or UV: Some high-quality suppliers include amino acid analysis (AAA) to confirm actual peptide content, which is more informative than HPLC purity alone.

Independent Verification Approaches

Researchers with access to a mass spectrometry core facility can perform independent identity confirmation by dissolving a small aliquot (1-2 mcg) in water:acetonitrile (1:1 with 0.1% formic acid) and running an LC-MS/MS analysis. Matching the fragmentation spectrum to the known sequence of the 24-aa MGF E-peptide provides a high-confidence identity confirmation that is independent of the vendor's own CoA.

For cell-based purity validation, a proliferation assay using primary murine satellite cells (C2C12 cells in a serum-restricted, sub-differentiation medium are a common proxy) provides functional verification that the batch elicits expected biological activity. A batch showing HPLC purity above 98% but no activity in a C2C12 proliferation assay would suggest either a sequence error or a conformational issue that mass spectrometry alone would not detect. This type of bioassay validation is not standard practice in most research labs but is worth considering for critical experiments.

Apollo Peptide Sciences lists third-party HPLC and mass spectrometry data on product pages for their catalog. Researchers are advised to request batch-specific CoAs rather than relying on a single representative document, as batch-to-batch variation exists across all synthetic peptide manufacturers.

Dosage and Reconstitution

Research Dose Ranges from Published Literature

The dose ranges used across the major MGF studies span several orders of magnitude depending on the model, endpoint, and form of peptide used:

• In the Deng et al. cardiac ischemia study, the synthetic E-peptide was administered intravenously in rats at 1, 10, and 100 nmol/kg body weight. At a rat body weight of approximately 250 g and a peptide molecular weight of approximately 2,867 Da, the 100 nmol/kg dose equates to approximately 72 mcg/250 g animal, or approximately 287 mcg/kg. ^[11]

• In the Qin et al. hindlimb ischemia study, PEG-MGF was administered intramuscularly at 25 mcg/kg body weight in rats. ^[2]

• In the Yang and Goldspink gene-transfer study, direct comparison to a systemic peptide dose is not possible, but the local intramuscular expression levels achieved by electrotransfer were estimated by the authors at nanomolar concentrations in the muscle compartment. ^[1]

• In cell culture experiments, the MGF E-peptide has been used at concentrations ranging from 10 nM to 1,000 nM, with most proliferative effects observed in the 50-200 nM range in satellite cell and cardiomyocyte assays. ^[6]

Reconstitution Protocol for a 2mg MGF Vial

The following numerical examples are drawn from general peptide research practice and the specific properties of MGF as described in the literature. All calculations assume a 2 mg vial with a true peptide content of 1.95 mg (accounting for approximately 2.5% water and counterion content, typical for lyophilized peptides).

Example 1, Stock solution at 1 mg/mL (1,000 mcg/mL): Add 2.0 mL of bacteriostatic water (or 0.6% acetic acid in sterile water) to the vial. Each 100 mcL withdrawn provides approximately 100 mcg of peptide. This concentration is practical for in-vivo rodent experiments where doses in the mcg/kg range require small injection volumes.

Example 2, Stock solution at 0.5 mg/mL (500 mcg/mL) for cell culture: Add 4.0 mL of sterile water for injection to the vial. For a cell culture experiment targeting a final concentration of 100 nM in a 1 mL well (in 24-well plate format), calculate as follows: Molecular weight approximately 2,867 Da; 100 nM in 1 mL = 100 nmol/L x 0.001 L = 0.1 nmol = 0.287 mcg. Using the 500 mcg/mL stock, 0.287 mcg requires 0.574 mcL of stock solution. This volume can be delivered using a calibrated Hamilton syringe or a 0.5-10 mcL pipette. Note that volumes below 1 mcL introduce significant pipetting error; for most 96-well or 24-well plate assays, preparing an intermediate dilution of the stock to approximately 10-50 mcg/mL before the final cell culture dilution reduces pipetting error substantially.

Example 3, Dosing calculation for rat in-vivo experiment using literature dose: Target dose: 25 mcg/kg (matching the Qin et al. PEG-MGF dose as a reference point, assuming the researcher substitutes native MGF for comparison). Rat body weight: 300 g = 0.3 kg. Required dose: 25 mcg/kg x 0.3 kg = 7.5 mcg. Using a 1 mg/mL stock: volume required = 7.5 mcg / 1,000 mcg/mL = 0.0075 mL = 7.5 mcL. This volume is at the lower edge of practical injection accuracy with a standard 1 mL insulin syringe. Researchers may prefer to dilute the stock to 100 mcg/mL (1:10 dilution with sterile saline or bacteriostatic water), making the injection volume 75 mcL, which is easily delivered by intramuscular or subcutaneous injection in a 300 g rat.

For detailed reconstitution technique including aseptic reconstitution procedure, solvent selection rationale, pH considerations, and storage after reconstitution, refer to our comprehensive peptide reconstitution guide.

Stability Considerations

Lyophilized MGF is stable at -20°C for at least 24 months according to standard peptide stability data, and at 4°C for at least 12 months in the absence of humidity. ^[16] Once reconstituted, the peptide should be stored at 2-8°C and used within 4 weeks for best results; repeated freeze-thaw cycles degrade peptide integrity through ice crystal formation and should be avoided by aliquoting the reconstituted stock into single-use volumes before freezing. For experiments requiring multiple dosing timepoints over weeks, single-use aliquots of the reconstituted peptide (stored at -80°C) are preferable to repeated thawing of a single vial.

Side Effects and Safety

Preclinical Safety Observations

Within the published animal literature, no acute toxicity signals have been reported at the research doses described in the studies reviewed above. Rodents receiving the synthetic MGF E-peptide or PEG-MGF at the doses cited in the Qin et al. and Deng et al. studies did not show gross behavioral abnormalities, weight loss, or organ pathology at study termination in the dosing periods examined (4 weeks in the ischemia studies). ^{[2] [11]}

This absence of reported toxicity should not be mistaken for a confirmed safety profile. The studies were not designed as toxicology studies; they were efficacy studies in which gross safety was a secondary observation. No formal maximum tolerated dose (MTD) study, no repeated-dose toxicology with systematic organ histopathology, and no carcinogenicity assessment has been published for MGF or PEG-MGF.

Theoretical Safety Concerns

Proliferative risk: MGF drives satellite cell proliferation and, in some in-vitro models, promotes survival of tumor cell lines. ^[17] The IGF axis is well-established as a mitogenic pathway, and several epidemiological studies have associated elevated circulating IGF-1 with increased risk of prostate, breast, and colorectal cancers. Whether MGF, acting through the E-peptide-specific pathway or through IGF-1R, contributes to or promotes tumorigenesis in intact animals is not established by any published study, but the theoretical concern is present and cannot be dismissed on current evidence.

Immunogenicity (PEG-MGF): PEGylated biologics have been associated with anti-PEG antibody formation in some patient populations receiving approved PEGylated drugs. ^[7] In the context of research animal models, pre-existing anti-PEG antibodies can accelerate clearance of PEGylated peptides (the "accelerated blood clearance" phenomenon) and confound pharmacokinetic studies. Researchers using PEG-MGF in chronic multi-dosing paradigms should consider baseline anti-PEG antibody measurement.

IGFBP interaction: Exogenous IGF-1 domain-containing peptides could theoretically displace endogenous IGF-1 from IGFBP-3, transiently increasing free IGF-1 levels in vivo beyond what the exogenous peptide itself contributes. This displacement mechanism has been observed with IGF-1 analogs and could complicate interpretation of experiments where the baseline IGF axis activity is a critical variable.

Endotoxin contamination risk: As described in the Purity section, inadequately tested preparations may carry endotoxin levels sufficient to activate TLR4-mediated inflammatory signaling, which could confound any experiment measuring survival, proliferation, or apoptosis endpoints in cell culture. This is a general risk for all synthetic peptides and is not unique to MGF, but it is worth reiterating here in the safety context.

How It Compares

MGF vs IGF-1 LR3

IGF-1 LR3 is a synthetic analog of IGF-1 in which the first three N-terminal amino acids are replaced by an arginine (R3) and a 13-amino-acid extension peptide is added to the N-terminus. These modifications reduce IGFBP binding by approximately 1,000-fold compared to native IGF-1 and extend the plasma half-life to approximately 20-30 hours. ^[8] In terms of IGF-1R binding and downstream Akt/mTOR activation, IGF-1 LR3 and MGF (via its mature IGF-1 domain) are mechanistically convergent. The key pharmacological distinction is that MGF E-peptide may activate satellite cell proliferation through an IGF-1R-independent pathway, which IGF-1 LR3 does not replicate. Researchers interested specifically in the satellite cell expansion component of muscle hypertrophy have a rationale for preferring MGF or PEG-MGF over IGF-1 LR3, though direct head-to-head comparison studies in satellite cell models are limited.

MGF vs PEG-MGF

The choice between native MGF and PEG-MGF depends almost entirely on the experimental design requirements. For acute signaling studies (measuring Akt or ERK phosphorylation within 30-60 minutes of peptide addition in cell culture), native MGF at equimolar concentrations is generally preferred because PEGylation can modestly reduce receptor binding kinetics and the PEG chain itself may interact nonspecifically with cell surface proteoglycans in some assay formats. For chronic in-vivo models, PEG-MGF is substantially more appropriate given the dramatically improved pharmacokinetic profile. ^[2] Cost is also a relevant consideration: PEG-MGF vials are typically priced 50-100% higher than equivalent native MGF vials, reflecting the added synthesis and characterization steps required for PEGylation.

MGF vs BPC-157

BPC-157 and MGF occupy different mechanistic spaces despite both appearing in muscle and tissue repair research contexts. BPC-157 is a 15-amino-acid gastric pentadecapeptide fragment with a strong published record in tendon, ligament, gut, and angiogenesis models, operating largely through upregulation of early growth response 1 (EGR-1) and nitric oxide (NO) signaling. ^[18] MGF, as reviewed throughout this article, acts primarily through IGF-1 axis receptors and satellite cell biology. Researchers designing combined regenerative protocols may find both peptides relevant but should treat them as mechanistically additive rather than redundant. For a detailed review of BPC-157, see our BPC-157 product review.

Where to Buy

Apollo Peptide Sciences supplies this MGF 2mg vial at the $20.00 price point reviewed in this article. The vendor's catalog is accessible through our internal MGF product listing, which provides the affiliate-linked purchasing path for researchers wishing to source through our vetted supplier network.

Before purchasing any research peptide, we recommend reviewing the current supplier landscape using our peptide supplier comparison guide. Key criteria for MGF specifically include batch-specific CoA availability (HPLC + MS), endotoxin testing results, and vendor response to technical queries about synthesis method and E-peptide sequence (native human 24-aa sequence versus alternative sequences should be explicitly confirmed). Price per milligram varies substantially across vendors, ranging from approximately $10/mg to $30/mg for native MGF; low price alone does not indicate acceptable quality, and several vendors marketing under the "MGF" label have been found in independent testing to supply truncated or missequenced peptide.

For researchers outside the United States, customs regulations governing importation of research peptides vary by jurisdiction. Review our international supplier guide and consult applicable local regulations before placing any order.

FAQ